Capital International Investors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Capital International Investors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,602,229	Closed	-$175M	–	464
2023 Q1	$175M	Sell	1,602,229 -7,702,586	-83%	-$851M	0.05%	245
2022 Q4	$1.06B	Buy	9,304,815 +682,205	+8%	+$56.7M	0.28%	94
2022 Q3	$534M	Buy	8,622,610 +957,225	+12%	+$66.9M	0.16%	142
2022 Q2	$611M	Buy	7,665,385 +589,728	+8%	+$55.8M	0.17%	137
2022 Q1	$744M	Buy	+7,075,657	New	+$690M	0.17%	137

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Capital International Investors's HZNP Position: Q2 2023 in Review

Capital International Investors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 1,602,229 shares — an estimated $175M sold.

Capital International Investors first reported a position in HZNP in Q1 2022 and held it in 5 quarters. The position peaked at $1.06B in Q4 2022. 519 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

Capital International Investors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
Capital International Investors sold 1,602,229 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $175M.
Capital International Investors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2022 and held it in 5 quarters.
Capital International Investors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.06B in Q4 2022.
519 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on Capital International Investors's 13F filing for Q2 2023, filed 11 Aug 2023.